Drug intelligence / Profile preview

MRANK-808

Development stage: Preclinical
Lead developer: MindRank
Modality: Small Molecules

Overview

MRANK-808 is a preclinical-stage small molecule drug candidate developed by MindRank for the treatment of obesity. Discovered through MindRank's proprietary AI-driven drug discovery platform, the compound's specific biological target is currently undisclosed. It represents part of the company's metabolic disease pipeline, which utilizes artificial intelligence to optimize drug-like properties and accelerate the transition from discovery to clinical development.

Beyond the preview

Go deeper on MRANK-808.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRANK-808.

Explore the full profile